Back to top

data://text/plain;base64,MA==
data://text/plain;base64,QkFZUlk=
http://widget3-stage.zacks.com/microcap/is_microcap_ticker/json/BAYRY
more

data://text/plain;base64,QkFZUlk=
http://quote-feed-stage.zacks.com/BAYRY
http://widget3-stage.zacks.com/stocks/data/json/BAYRY
http://widget3-stage.zacks.com/quote/scorecard/json/BAYRY
http://widget3-stage.zacks.com/stocks/data/json/BAYRY

Bayer (BAYRY)

(Delayed Data from OTC)

$14.25 USD

14.25
370,615

+0.23 (1.64%)

Updated Aug 31, 2026 03:59 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.80%
2Buy18.13%
3Hold10.19%
4Sell5.73%
5Strong Sell3.17%
S&P50011.53%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 41% (101 out of 248)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks


http://widget3-stage.zacks.com/archive/text/json/1/QkFZUlk=

Zacks News

Zacks Equity Research

Gilead Resolves Patent Litigations for HIV Treatment Biktarvy

by Zacks Equity Research

Gilead's settlement on Biktarvy patents delays generic entry until 2036, boosting investor confidence.

Zacks Equity Research

Can CYTK Clinch a Potential FDA Nod for Its Cardiovascular Drug?

by Zacks Equity Research

Cytokinetics' aficamten shows superiority over metoprolol in late-stage oHCM trial, boosting investor confidence despite FDA delay.

Zacks Equity Research

Best Value Stock to Buy for September 26th

by Zacks Equity Research

BAYRY, CARS and MRX made it to the Zacks Rank #1 (Strong Buy) value stocks list on September 26, 2025.

Zacks Equity Research

Are Medical Stocks Lagging Adagene (ADAG) This Year?

by Zacks Equity Research

Here is how Adagene Inc. Sponsored ADR (ADAG) and Bayer Aktiengesellschaft (BAYRY) have performed compared to their sector so far this year.

Zacks Equity Research

REGN Loses 21.1% Year to Date: Buy, Sell or Hold the Sock?

by Zacks Equity Research

Regeneron shares slump as Eylea struggles, but Dupixent gains and a strengthening oncology pipeline offer growth potential.

Zacks Equity Research

Zacks Industry Outlook Highlights Eli Lilly, Johnson & Johnson, Novartis, Pfizer and Bayer

by Zacks Equity Research

Big Pharma faces tariff risks, patent cliffs, and regulatory pressure, but innovation and strong pipelines keep Eli Lilly, J&J, Novartis, Pfizer, and Bayer in focus.

Kinjel Shah headshot

5 Large Drug Stocks to Watch Despite Industry & Macro Headwinds

by Kinjel Shah

In the Large-Cap Pharmaceuticals industry, Lilly, J&J, Novartis, Pfizer and Bayer are worth retaining amid macro pressure and rising innovation.

Zacks Equity Research

Are Medical Stocks Lagging Bayer (BAYRY) This Year?

by Zacks Equity Research

Here is how Bayer Aktiengesellschaft (BAYRY) and BioLife Solutions, Inc. (BLFS) have performed compared to their sector so far this year.

Zacks Equity Research

RHHBY Posts Positive Data on Vabysmo in nAMD at Euretina Congress

by Zacks Equity Research

Roche posts strong new data for Vabysmo in eye disease, with extended dosing and vision gains driving growth.

Zacks Equity Research

Should Value Investors Buy Bayer (BAYRY) Stock?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.